Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma in Focus Jobs
Farmaforce
Latest News
HCV script binge hits a peak
Reimbursement: July PBS figures indicate that monthly scripts for new hep C medicines may have peaked in the June quarter.
PM's diary delaying Sansom response
Regulatory Reform: The government has its response to the Sansom regulatory review in hand but a desire for Prime Minister Malcolm Turnbull to be involved announcing it is delaying a release Pharma in Focus has been told.
Linfox takes on DHL in pharma logistics
Services: Logistics giant Linfox has built a brand new $53 million pharma specific facility and says it is set to take on DHL in drug distribution.
Voters don't care for innovation
Policy Choices: A big majority of Australians believes that health policy should be the government's number one priority; very few think it should be innovation.
Pharma product liability threat fades
Litigation: Despite changes in the law, the days of product liability actions against drug makers seem pretty much numbered in Australia.
Overdose training needed with Rx meds
Medicines Safety: Targeted overdose training should be introduced for Australians prescribed with opioids and benzodiazepines to combat the growing risk of death, according to a leading substance abuse advocacy group.
Most Popular
Gilead breaks $1b, hits the top
Reimbursement: Gilead has charged through the $1 billion barrier in R/PBS benefits and surged to the top of Australia's top ten pharma companies.
Pfizer continues buying spree
Acquisitions: US giant will pay up to $1.5 billion to AstraZeneca for the UK company's small molecule anti-infective portfolio.
MA appoints new CEO
Medicines Australia has named its new permanent CEO to replace interim CEO Lee Hill whose current role officially finishes at the end of next month.
How pharma can learn from Uber
Marketing: The driving force behind MSD's SEA digital expansion says pharma is too insular on digital and points to finance sector as a place to learn.
Pfizer makes PBAC change its mind
Reimbursement: Pfizer has persuaded the PBAC to change its mind on the cost-effectiveness of pneumococcal vax Prevenar 13 and is now calling for a quick NIP listing.
Earlier
Novartis to divest Roche stake: reports
Companies: Novartis is reported to be acting on plans revealed earlier this year to sell its US$14b stake in Roche with a view to funding another acquisition.
Sansom silence a puzzle to all
Regulatory Reform: Fourteen months since the first recommendations of the Sansom review were released, the silence from government has everyone puzzled but are there signs of life?
PrEP resubmission on the cards
Medicines Access: Gilead says its rejected PrEP submission is under review with a return to the PBAC in prospect but there are more issues than price alone.
Hep C patient groups mark pharma
Reputation: And international study among patient groups that includes Australia has rated pharmacos operating in the hepatitis C space high for innovation but low on pricing policy.
Debating Point
Has biosim a-flagging backfired?
The PBAC's enthusiastic approach to a-flagging biosims as they come up for reimbursement has so far led to medical mistrust, withdrawal of one major biosim and slow uptake of those that have been listed. Is it time for a re-think?
Approvals Action
First challenge to psoriasis treatment
Sandoz has registered the frst new generic brand against Leo Pharma's PBS listed psoriasis treatment Daivobet.
Pipeline Monitor
Pfizer scores pain win
Pfizer's new tamper proof opioid Troxyca ER has been approved in the US for the management of severe pain for which alternative treatment options are inadequate.
PBAC Agenda
PBAC faces massive list for November meeting
The agenda for the November PBAC meeeting presents the committee with a massive list of submissions, totalling 59 in all, 25 of which are major submissions.
FREE Content
Events & Conferences
SEARCH NOW
Pharma in Focus Jobs
Ascott Sales